- Home
- NCDL vs ADPT Comparison
NCDL vs ADPT Comparison
Compare NCDL & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- ADPT
- Stock Information
- Founded
- NCDL 2019
- ADPT 2009
- Country
- NCDL United States
- ADPT United States
- Employees
- NCDL N/A
- ADPT N/A
- Industry
- NCDL
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCDL
- ADPT Health Care
- Exchange
- NCDL NYSE
- ADPT Nasdaq
- Market Cap
- NCDL 919.2M
- ADPT 929.8M
- IPO Year
- NCDL N/A
- ADPT 2019
- Fundamental
- Price
- NCDL $16.96
- ADPT $7.45
- Analyst Decision
- NCDL Buy
- ADPT Buy
- Analyst Count
- NCDL 6
- ADPT 4
- Target Price
- NCDL $18.33
- ADPT $6.75
- AVG Volume (30 Days)
- NCDL 313.8K
- ADPT 1.3M
- Earning Date
- NCDL 02-22-2025
- ADPT 02-12-2025
- Dividend Yield
- NCDL 7.95%
- ADPT N/A
- EPS Growth
- NCDL N/A
- ADPT N/A
- EPS
- NCDL N/A
- ADPT N/A
- Revenue
- NCDL N/A
- ADPT $177,282,000.00
- Revenue This Year
- NCDL N/A
- ADPT $6.48
- Revenue Next Year
- NCDL N/A
- ADPT $18.72
- P/E Ratio
- NCDL N/A
- ADPT N/A
- Revenue Growth
- NCDL N/A
- ADPT N/A
- 52 Week Low
- NCDL $16.00
- ADPT $2.28
- 52 Week High
- NCDL $18.10
- ADPT $7.50
- Technical
- Relative Strength Index (RSI)
- NCDL 55.63
- ADPT 61.48
- Support Level
- NCDL $16.20
- ADPT $5.98
- Resistance Level
- NCDL $16.96
- ADPT $7.28
- Average True Range (ATR)
- NCDL 0.28
- ADPT 0.56
- MACD
- NCDL 0.04
- ADPT 0.04
- Stochastic Oscillator
- NCDL 83.52
- ADPT 96.86
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).